Division of Epidemiology, Department of Environmental Medicine, NYU School of Medicine; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York. Division of Urologic Surgery and Department of Genetics, Washington University School of Medicine, St. Louis, Missouri; Division of Cancer Prevention and Control, Moffitt Cancer Center, Tampa, Florida; Center for Clinical Epidemiology and Biostatistics and Abramson Cancer Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health; Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health; Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland; and Department of Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Genome-wide association studies (GWAS) have identified multiple novel prostate cancer predisposition loci. Whether these common genetic variants are associated with incident metastatic prostate cancer or with recurrence after surgical treatment for clinically localized prostate cancer is uncertain.
Twelve single nucleotide polymorphisms (SNPs) were selected for study in relation to prostate metastatic cancer and recurrence, based on their genome-wide association with prostate cancer in the Cancer Genetic Markers of Susceptibility (CGEMS). To assess risk for metastatic disease, we compared genotypes for the 12 SNPs by logistic regression of 470 incident metastatic prostate cancer cases and 1,945 controls in 3 case-control studies. To assess the relationship of these SNPs to risk for prostate cancer recurrence, we used Cox regression in a cohort of 1,412 men treated for localized prostate cancer, including 328 recurrences, and used logistic regression in a case-case study, comparing 450 recurrent versus 450 nonrecurrent prostate cancer cases. Study-specific relative risks (RRs) for risk of metastatic disease and recurrence were summarized using meta-analysis, with inverse variance weights.
MSMB rs10993994 (per variant allele summary RR = 1.24, 95% CI = 1.05-1.48), 8q24 rs4242382 (RR = 1.40, 95% CI = 1.13-1.75), and 8q24 rs6983267 (RR = 0.67, 95% CI = 0.50-0.89) were associated with risk for metastatic prostate cancer. None of the 12 SNPs was associated with prostate cancer recurrence.
SNPs in MSMB and 8q24 which predispose to prostate cancer overall are associated with risk for metastatic prostate cancer, the most lethal form of this disease. SNPs predictive of prostate cancer recurrence were not identified, among the predisposition SNPs. GWAS specific to these 2 phenotypes may identify additional phenotype-specific genetic determinants.
Ahn J, Kibel AS, Park JY, Rebbeck TR, Rennert H, Stanford JL, Ostrander EA, Chanock S, Wang MH, Mittal RD, Isaacs WB, Platz EA, Hayes RB. Are you the author?
Reference: Clin Cancer Res. 2011 Mar 1;17(5):1075-1081.